{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["15(2)"],"submitter":["Thoueille P"],"funding":["World Anti-Doping Agency"],"pubmed_abstract":["Salmeterol is a commonly used β<sub>2</sub>-agonist included on the List of Prohibited Substances and Methods published by the World Anti-Doping Agency (WADA). We developed a population pharmacokinetic (popPK) model to describe the PK of salmeterol including its major metabolite, α-hydroxysalmeterol, in plasma and urine after inhalation. The model was used to evaluate the ability of the current minimum reporting level (MRL) of 10 ng/mL for salmeterol to discriminate between permitted and prohibited use of salmeterol. Six studies on healthy participants, chronic asthmatics, or athletes were pooled and provided a total of 1175 concentrations (275 and 398 for salmeterol and 185 and 317 for α-hydroxysalmeterol in plasma and urine, respectively) from 92 individuals. A two-compartment model assu"],"journal":["CPT: pharmacometrics & systems pharmacology"],"pagination":["e70187"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC12823318"],"repository":["biostudies-literature"],"pubmed_title":["Pharmacometric-Based Evaluation of Salmeterol and Its Metabolite α-Hydroxysalmeterol in Plasma and Urine: Practical Implications for Doping Control."],"pmcid":["PMC12823318"],"pubmed_authors":["Mazzoni I","Danion A","Guidi M","Petrou M","Deventer K","Girardin FR","Thoueille P","Buclin T","Rabin O","Hostrup M"],"additional_accession":[]},"is_claimable":false,"name":"Pharmacometric-Based Evaluation of Salmeterol and Its Metabolite α-Hydroxysalmeterol in Plasma and Urine: Practical Implications for Doping Control.","description":"Salmeterol is a commonly used β<sub>2</sub>-agonist included on the List of Prohibited Substances and Methods published by the World Anti-Doping Agency (WADA). We developed a population pharmacokinetic (popPK) model to describe the PK of salmeterol including its major metabolite, α-hydroxysalmeterol, in plasma and urine after inhalation. The model was used to evaluate the ability of the current minimum reporting level (MRL) of 10 ng/mL for salmeterol to discriminate between permitted and prohibited use of salmeterol. Six studies on healthy participants, chronic asthmatics, or athletes were pooled and provided a total of 1175 concentrations (275 and 398 for salmeterol and 185 and 317 for α-hydroxysalmeterol in plasma and urine, respectively) from 92 individuals. A two-compartment model assu","dates":{"release":"2026-01-01T00:00:00Z","publication":"2026 Feb","modification":"2026-06-06T19:27:58.004Z","creation":"2026-06-04T03:10:29.787Z"},"accession":"S-EPMC12823318","cross_references":{"pubmed":["41543451"],"doi":["10.1002/psp4.70187"]}}